SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.72 / 10
Outperform
Analyst consensus is overwhelmingly bullish: two strong‑buy ratings (100%). Fund‑flow score is 7.95/10, with positive inflows across most investor sizes except large blocks. Sentiment rating is Outperform, supporting a favorable short‑term outlook.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-18
InstitutionStifel
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of SYRE?
- SYRE holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.72/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
